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Abstract
AIM
To determine the prevalence of work disability in 
inflammatory bowel disease (IBD), and to assess risk 
factors associated with work disability.
METHODS
For this retrospective cohort study, we retrieved 
clinical data from the Dutch IBD Biobank on July 2014, 
containing electronic patient records of 3388 IBD 
patients treated in the eight University Medical Centers 
in the Netherlands. Prevalence of work disability was 
assessed in 2794 IBD patients and compared with the 
general Dutch population. Multivariate analyses were 
performed for work disability (sick leave, partial and 
full disability) and long-term full work disability (> 80% 
work disability for > 2 years).
RESULTS
Prevalence of work disability was higher in Crohn’s 
disease (CD) (29%) and ulcerative colitis (UC) (19%) 
patients compared to the general Dutch population 
(7%). In all IBD patients, female sex, a lower education 
level, and extra-intestinal manifestations, were 
associated with work disability. In CD patients, an age 
> 40 years at diagnosis, disease duration > 15 years, 
smoking, surgical interventions, and anti-TNFα use 
were associated with work disability. In UC patients, 
an age > 55 years, and immunomodulator use were 
associated with work disability. In CD patients, a lower 
education level (OR = 1.62, 95%CI: 1.02-2.58), and in 
UC patients, disease complications (OR = 3.39, 95%CI: 
1.09-10.58) were associated with long-term full work 
disability.
CONCLUSION
The prevalence of work disability in IBD patients is 
higher than in the general Dutch population. Early 
assessment of risk factors for work disability is 
necessary, as work disability is substantial among IBD 
patients. 
Key words: Inflammatory bowel disease; Crohn’s 
disease; Ulcerative colitis; Work disability; Health care 
costs
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Our study shows that a lower education 
is patients with Crohn’s disease, and disease com-
plications (osteopenia, thromboembolic event) in 
patients with ulcerative colitis are associated with long-
term full work disability (> 80% work disability for > 2 
years). This highlights the need for early assessment 
of risk factors for work disability, as work disability is 
substantial among inflammatory bowel disease patients 
and associated with high societal health care costs. 
Spekhorst LM, Oldenburg B, van Bodegraven AA, de Jong DJ, 
Imhann F, van der Meulen­de Jong AE, Pierik MJ, van der Woude 
JC, Dijkstra G, D’Haens G, Löwenberg M, Weersma RK, Festen 
EAM; Parelsnoer Institute and the Dutch Initiative on Crohn 
and Colitis. Prevalence of­ and risk factors for work disability 
in Dutch patients with inflammatory bowel disease. World J 
Gastroenterol 2017; 23(46): 8182­8192  Available from: URL: 
http://www.wjgnet.com/1007­9327/full/v23/i46/8182.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v23.i46.8182
INTRODUCTION
Inflammatory bowel disease (IBD), consisting of 
Crohn’s disease (CD) and ulcerative colitis (UC) is a 
heterogeneous/multifaceted disease. Patients suffer 
from symptoms like diarrhoea, abdominal pain, fatigue, 
and weight loss. The disease course is unpredictable, 
complicated by flares, need for chronic medication use 
and need for surgery. This leads to increasing intestinal 
damage with a high disease burden in many patients 
with IBD[1]. It has been established that, depending on 
disease activity, patients with IBD experience a lower 
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quality of life[2,3]. IBD generally makes its debut during 
the second or third decade of life. Therefore, patients 
with IBD can encounter major problems during their 
economically productive life, which can lead to work 
disability, sometimes at young age. Work disability in 
patients with IBD is associated with a further decrease 
in quality of life, and high societal costs, especially 
if work disability is long-term and arises at a young 
age[4,5]. Preventing work disability is therefore an 
important goal in IBD management. 
Work disability rates have been reported before, but 
reported rates are heterogeneous, ranging between 
5% and 33% depending on sample size, methodology, 
and study population[6-12]. Several clinical factors have 
been suggested to play a role in work disability, such 
as female sex, age, disease duration, disease severity, 
and surgical interventions[10-16]. However, in most study 
designs, risk factors for any form of work disability are 
the focus of interest, neglecting risk factors associated 
specifically with long-term full work disability (> 80% 
work disability for > 2 years).
Therefore, our aims were: (1) to assess the 
prevalence of work disability in patients with IBD and 
to compare this with the general Dutch population; 
and (2) to identify risk factors for work disability, 
especially risk factors for long-term full work disability.
MATERIALS AND METHODS
Study design and study population
For this study, we used data from the Dutch IBD 
Biobank, which is part of the Parelsnoer Institute (www.
parelsnoer.org). Since 2007, every patient with IBD 
that is treated in one of the eight Dutch University 
Medical Centers (UMCs) is invited to participate. 
The data is collected prospectively and patients with 
IBD are being enrolled continuously. Clinical data is 
retrieved from medical records by using a standardized 
information model containing 225 IBD related items. 
Items used for this study are; demographic items, 
diagnosis, smoking status, employment status, 
disease location, disease behaviour, education level, 
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Table 1  Definition of used parelsnoer information model items
Diagnosis of IBD
   Crohn’s disease
   Ulcerative colitis
   IBD-unclassified
   IBD-Indeterminate 
Diagnosis of IBD was defined by clinical symptoms of the disease and confirmed by endoscopy, radiology or 
histology. If differentiation between CD and UC was not possible, patient were classified as Inflammatory Bowel 
Disease Unclassified (IBD-U). In the case that a pathologist was not able to differentiate between CD or UC following 
colectomy, the patient was classified as Inflammatory Bowel Disease Indeterminate (IBD-I). 
Family history of IBD
Family history of IBD was registered up to 3rd degree relatives
Smoking status
Smoking status at diagnosis was documented. Patients were classified as never smokers, current smokers or former 
smokers
Education level
Patients were classified in two groups; low education (Lower general education; Lower vocational education; General 
secondary education; Vocational secondary education; Did not finish primary school) and high education (Pre-
university secondary education; Vocational post-secondary education; University)
Disease behavior Disease behavior is reported if it occurred at any point in the disease course up to baseline.
   Fistulising disease Fistulising disease is confirmed by physical examination, radiological or endoscopy assessment.
   Stricturing disease A stricture had to be symptomatic. 
An anal stenosis had to be symptomatic and confirmed by physical examination.
   Penetrating disease Penetrating disease is defined as an intestinal abscess or intestinal perforation due to disease activity. 
Prescribed medication
   Anti-tumor necrosis factor alpha Prescribed medication included anti-tumor necrosis factor alpha (TNF-alpha) agents (infliximab, adalimumab or 
certolizumab). Data on medication use was available for the entire disease course; medication use was therefore 
defined as medication ‘ever used’
   Immunomodulators immunomodulators (mercaptopurine, azathioprine, thioguanine or methotrexate). Data on medication use was 
available for the entire disease course; medication use was therefore defined as medication ‘ever used’
IBD-related surgical interventions
IBD-related surgical interventions included small bowel resection, ileocecal resection, colon resection, resection other, 
strictureplasty, ileostomy/colostomy, surgery for abscesses or fistula, stoma and pouch
Extra-intestinal manifestations 
   Skin manifestations Skin manifestations unrelated to the use of IBD medication such as pyoderma gangrenosum, erythema nodosum, 
hidradenitis suppurativa, psoriasis or palmoplantar psoriasiform pustolosis, and metastatic CD.
   Musculoskeletal manifestations Arthritis was defined as red and swollen joints, dactylitis, reactive arthritis and gout. 
Arthropathy was defined as painful joints, without any swelling or redness, with an inflammatory pattern: pain at 
night or at rest (e.g., sacroiliitis, ankylosing spondylitis, enthesitis, and inflammatory back pain).
   Ocular manifestations Ocular manifestations included uveitis and episcleritis.
Complications
   Osteopenia Osteopenia was defined as a bone mineral density T-score lower than -1.
   Thromboembolic event A thromboembolic event was confirmed by additional tests (radiology, endoscopy or histology).
IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis.
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Employment rates were collected for 2014 and matched 
for sex and age. 
Statistical analysis
In all analyses, patients with UC were grouped with 
patients with IBD-Unclassified (IBD-U) and IBD-
Indeterminate (IBD-I). Dichotomous variables were 
compared using the Pearson χ 2 test. Continuous 
variables were compared using the Mann-Whitney-U 
test. The Student t-test was used to compare overall 
work disability in our cohort to the general Dutch 
population. The variable “age” represented the age at 
inclusion at which employment status was assessed. To 
assess clinical predictors of work disability in patients 
with IBD, we categorized the variable employment status 
into two groups; employed (both full time and part time) 
and disabled for work (including partial disability, full 
disability and sick leave). Retirement and “other” were 
left out of the final analyses after we determined that 
“other” was unlikely to contain undeclared differential 
work disability, such as pregnancy leave. We performed 
a multivariate analysis with employment status as 
outcome and included demographic and clinical items 
that had a P < 0.10 in the univariate analysis for 
employment status. Analyses were repeated in patients 
with CD and patients with UC, separately. To assess risk 
factors for long-term full work disability, patients with 
full disability were compared to patients with partial 
disability. Statistical analyses were performed with Stata 
Software V.13.1[19].
RESULTS
Patient population and demographic characteristics
A total of 2794 patients with IBD were within working 
age and were included in the analysis; 1740 patients 
with CD and 1054 patients with UC. Demographic and 
clinical characteristics are depicted in Table 2. In our 
cohort, more patients with CD were female compared 
to patients with UC (63% vs 53%, P < 0.01). Age at 
diagnosis was lower in patients with CD compared 
surgery-related items, medication use, extra-intestinal 
manifestations and complications. Definitions of these 
items can be found in Table 1. At the moment of data 
freeze (the 17th of July 2014), the Dutch IBD Biobank 
contained 3388 patients with IBD. For this study, 
patients for whom employment status was missing 
were excluded. We only included adult patients with 
IBD within working age, and thus excluded patients 
over the age of 65 years. 
Definition of work disability
Patients were asked about their employment status 
at inclusion, which was defined using the following 
categories; (1) working full time (80%-100%, or 
working 30 h or more a week); (2) working part time 
(< 80%, or working less than 30 h a week); (3) partial 
work disability (35%-80% work disability for > 2 
years); (4) full work disability (> 80% work disability 
for > 2 years); (5) sick leave (work disability for < 2 
years); (6) retired; and (7) “Other”.
A Dutch law (“Wet werk en inkomen naar ar-
beidsvermogen” or WIA) prescribes that from the 
moment Dutch citizens are disabled to work they are 
entitled to receive a maximum of 170% of their wages 
during a period of 104 mo (generally 100% for 52 wk, 
followed by 70% for 52 wk). If after 104 mo the person 
is still on sick leave the same law prescribes whether 
patients receive a disability pension. There are two 
types of disability pension; partial disability (35%-80% 
work disability) and full disability (more than 80% 
work disability). A specialized physician determines the 
percentage of work disability based on questionnaires 
and physical examination. 
Due to the nature of our data we could not dis-
tinguish whether work disability was solely attributable 
to IBD or whether there was an additional cause. 
To compare the currently reported work disability 
rates with the general Dutch population we retrieved 
information from Statistics Netherlands (CBS), a 
national institute gathering statistical information about 
the Dutch population, including employment rates[17,18]. 
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Figure 1  Percentage of work disability per age category in females and males. Comparing work disability rates in patients with CD and patients with UC with the 
general Dutch population. A: Work disability in females; B: Work disability in males. CD: Crohn’s disease; UC: Ulcerative colitis.
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to patients with UC (24 years old vs 29 years old, P 
< 0.01). The prevalence of a family history positive 
for IBD (30% vs 25%, P = 0.01) as well as the 
appendectomy rate (15% vs 7%, P < 0.01) were 
higher in patients with CD. Patients with CD were more 
often smokers than patients with UC (27% vs 12%, P 
< 0.01). According to the Montreal classification, most 
patients with CD had ileocolonic disease [47% (L3)], 
whereas most patients with UC had an extensive colitis 
[58% (E3)] (Table 2).
Employment status in patients with IBD compared to the 
general Dutch population
Figure 1 shows the percentages of work disability in 
patients with CD, patients with UC and the general 
Dutch population per age category in females (Figure 
1A) and males (Figure 1B). Overall, work disability was 
significantly higher in IBD patients compared to the 
general Dutch population, independent of sex (P < 
0.05). 
Clinical risk factors of (long-term full) work disability in 
patients with CD
Table 3 depicts the (clinical) risk factors that were 
significantly associated with work disability in CD (548 
patients with CD were fully disabled and 966 patients 
with CD were employed). In the multivariate model, 
female sex (OR = 2.03, 95%CI: 1.53-2.69), an age > 
40 years at diagnosis (OR = 3.69, 95%CI: 1.83-7.42), 
a disease duration > 15 years (OR = 1.67, 95%CI: 
1.15-2.43), a lower education level (OR = 2.02, 95%CI: 
1.55-2.64), smoking (OR = 1.45, 95%CI: 1.09-1.92), 
surgical interventions (OR = 1.48, 95%CI: 1.10-2.00), 
anti- Tumor necrosis factor alpha (TNFα) use (OR = 1.86, 
95%CI: 1.43-2.43), and extra-intestinal manifestations 
(OR = 1.36, 95%CI: 1.05-1.77) were all associated 
with an increased odds ratio for work disability in CD. 
In the second analysis, partial disability was 
compared to long-term full work disability for CD. In 
the multivariate model, an age > 55 years (OR = 3.06, 
95%CI: 1.54-6.07), and a lower education level (OR 
= 1.62, 95%CI: 1.02-2.58) were associated with long-
term full work disability in CD (Table 4). 
Clinical risk factors of (long-term full) work disability in 
patients with UC 
In Table 5, (clinical) risk factors that were significantly 
associated with work disability in UC (214 patients 
Table 2  Demographic and clinical characteristics in patients with Crohn’s disease and ulcerative colitis n  (%)
CD UC P  value
n 1740 1054
Sex (female) 1103 (63)   561 (53)  < 0.01
Median age, yr, (IQR 25-75) 39.9 (30-51) 43.4 (33-53)  < 0.01
Median age diagnosis, yr, (IQR 25-75) 24.1 (19-32) 29.0 (22-39)  < 0.01
Median age disease duration, yr, (IQR 25-75) 11.7 (6-21) 10.3 (5-18)  < 0.01
Family history of IBD1  518 (30)  266 (25)   0.01
Appendectomy1  266 (15)  70 (7) < 0.01
Smoking 1620 (100)    984 (100)
   Yes  439 (27)   117 (12) < 0.01
Disease location
   L1: ileal disease2  324 (22)
   L2: colon disease2  450 (31)
   L3: ileocolon disease2  696 (47)
   L4: upper GI disease1 156 (9)
   P: peri-anal disease1   485 (28)
   E1: proctitis3  77 (8)
   E2: left-sided colitis3  315 (34)
   E3: extensive colitis3   541 (58)
Disease behavior CD
   Fistulising disease1 289 (17)
   Penetrating disease1 232 (13)
   Stricturing disease1 445 (26)
Education 1708 (100)  1036 (100)
   Low  932 (55)  517 (50)  0.02
Employment status 
   Full-time   607 (35)  440 (42)  < 0.01
   Part-time   359 (21)  224 (21)
   Partially disabled to work 129 (7)  54 (5)
   Fully disabled to work   342 (20)  124 (12)
   Sick leave   77 (4)  36 (3)
   Retired      22 (1.3)  21 (2)
   Other    204 (12)  155 (15)
1Missing values were scored as non-present; 2These percentages are calculated for 1470 patients with CD; 3These percentages are calculated for 993 patients 
with UC. CD: Crohn’s disease; UC: Ulcerative colitis.
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with UC were fully disabled and 664 patients with UC 
were employed) have been shown. In the multivariate 
model, female sex (OR = 1.76, 95%CI: 1.23-2.53), 
an age > 55 years (OR = 2.93, 95%CI: 1.68-5.14), a 
lower education level (OR = 2.59, 95%CI: 1.81-3.70), 
immunomodulator use (OR = 1.58, 95%CI: 1.09-2.28), 
and extra-intestinal manifestations (OR = 2.13, 95%CI: 
1.47-3.09) were all associated with an increased odds 
ratio for work disability in UC. 
In the second analysis, partial disability was 
compared to long-term full work disability for UC. In 
the multivariate model, an age > 55 years (OR = 3.49, 
95%CI: 1.23-9.92), and complications (OR = 3.39, 
95%CI: 1.09-10.58) were associated with long-term 
full work disability in UC (Table 6).
DISCUSSION
In this nationwide clinical database and biobank study 
we assessed work disability rates in patients with IBD. 
We found higher rates of work disability in patients 
with IBD compared to the general Dutch population. 
Furthermore, in patients with IBD female sex, a lower 
education level, and extra-intestinal manifestations were 
significantly associated with work disability. In patients 
with CD, an age > 40 years at diagnosis, disease 
duration > 15 years, smoking, surgical interventions, 
and anti-TNFα use were significantly associated with 
higher work disability. In patients with UC, an age > 
55 years, and immunomodulator use were significantly 
associated with higher work disability. In patients with 
CD a lower education level was associated with long-
term full work disability, whereas in patients with UC 
disease complications were associated with long-term 
full work disability.  
High work disability rates in patients with IBD 
In patients with IBD, the overall proportion of work 
disability was 29% in CD, and 19% in UC. These work 
disability rates were higher than those in the age-
adjusted general Dutch population (7%). Suffering 
from (severe) IBD may in itself be explanatory for this 
Table 3  Univariate and multivariate regression analyses of work disability in patients with Crohn’s disease n  (%)
Work disability Employed Unadj. OR (95%CI) Adj. OR (95%CI)
n   548 (100)   966 (100)
Sex (female)  397 (72)  556 (58)  1.94 (1.55-2.43)  2.03 (1.53-2.69)
Age, yr
   < 40  215 (39) 537 (55) 1.00 1.00
   40-55  220 (40) 335 (35) 1.64 (1.30-2.07) 0.94 (0.65-1.35)
   > 55  113 (21)   94 (10) 3.00 (2.19-4.12) 1.63 (0.95-2.77)
Age at diagnosis, yr
   A1: diagnosis ≤ 16 47 (9) 156 (16) 1.00 1.00
   A2: diagnosis 17-40  413 (75) 719 (75)  1.91 (1.35-2.70) 2.02 (1.30-3.13)
   A3: diagnosis > 40   88 (16)  91 (9)  3.21 (2.07-4.98) 3.69 (1.83-7.42)
Disease duration, yr
   ≤ 15  285 (52)  618 (64) 1.00 1.00
   > 15  263 (48) 348 (36)  1.64 (1.32-2.03) 1.67 (1.15-2.43)
Education    537 (100)   950 (100)
   Low  366 (68) 446 (47)  2.42 (1.94-3.02)  2.02 (1.55-2.64)  
Smoking   508 (100)   904 (100)
   Yes 180 (35) 203 (22)  1.90 (1.49-2.41)  1.45 (1.09-1.92)
Disease location
   L1: ileal disease1   88 (19) 184 (23) 1.00 1.00
   L2: colon disease1  138 (30) 263 (33)   1.10 (0.79-1.52)  1.10 (0.75-1.61)
   L3: ileocolon disease1  237 (51) 359 (44)   1.38 (1.02-1.87)  1.29 (0.91-1.83)
   L4: upper GI disease2  52 (9) 82 (8)   1.13 (0.79-1.63) -
   P: peri-anal disease2 170 (31) 256 (26)   1.25 (0.99-1.57)  1.03 (0.77-1.37)
Disease behavior CD
   Fistulising disease2   95 (17) 156 (16)  1.09 (0.82-1.44) -
   Stricturing disease2  145 (26) 248 (26)  1.04 (0.82-1.32) -
   Penetrating disease2    72 (13) 128 (13)  0.99 (0.73-1.35)  -
   Pouch2  12 (2)    17 (1.8)  1.25 (0.59-2.64) -
   Stoma2   96 (18) 108 (11)  1.69 (1.25-2.27)  1.15 (0.78-1.69)
   Surgery2  288 (53) 406 (42)  1.53 (1.24-1.89)  1.48 (1.10-2.00)
Medication    537 (100)   949 (100)
   Anti-TNFα 309 (58) 435 (46)  1.60 (1.29-1.98)   1.86 (1.43-2.43)
   Immunomodulators 395 (74) 698 (74)  1.00 (0.79-1.27) -
   Extra-intestinal manifestations2 229 (42) 294 (30)  1.64 (1.32-2.04)  1.36 (1.05-1.77)
   PSC2      7 (1.3)    14 (1.5)  0.88 (0.35-2.19) -
   Complications2  155 (28)  223 (23)   1.31 (1.04-1.67)  1.18 (0.88-1.59)
1These percentages are calculated for 463 patients with CD that were disabled for work and 806 patients with CD that were employed; 2Missing values were 
scored as non-present. CD: Crohn’s disease; Unadj: Unadjusted; TNFα: Tumor necrosis factor alpha; PSC: Primary sclerosing cholangitis.
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higher percentage. Furthermore, all patients in the 
Dutch IBD Biobank were treated in tertiary referral 
centers with a severe disease course signature: 
47% ileocolonic disease (L3 Montreal CD) and 58% 
extensive colitis (E3 Montreal UC). Indeed, disease in 
remission was associated with increased employment 
in CD[5] whereas disease severity was a predictor of 
work disability in IBD[16]. 
Criteria for disability pension differ between countries 
due to political and socioeconomic factors. Comparison 
of work disability rates between different countries is 
therefore difficult. In addition, differences in selection 
criteria, study methodology, sample size, and definitions 
of work disability result in highly variable disability rates 
reported (from 5% to 33%)[6-14]. In two comparable 
Dutch IBD-population studies it has been concluded by 
the authors that disability rates in CD and in UC were 
higher compared to the general Dutch population, 
which is in line with the current results. However, work 
disability rates of 33% in CD, 24% in UC, and 11% in 
the control population were reported in the first study 
that was conducted in 2002[8], which is higher than the 
disability rates we found. This may be due to changes 
in the welfare system since 2002, when patients got a 
disability pension after one year of sick leave, instead of 
after two years as it is now. Disability rates in a second, 
more recent Dutch study, by van der Valk et al[10], were 
more in line with our findings but lower (18% in CD, 
10% in UC, and 7% in the control population). Although 
there seems to be a wide range in work disability 
rates in IBD, it may be concluded that the rate of work 
disability is substantial among patients with IBD. 
Clinical risk factor for work disability
Female sex[10,11,13,15,16], an age > 40 years at dia-
gnosis[11,13], older age at inclusion[10,12,13,15,16], a 
lower education level[10,13], extra-intestinal ma-
nifestations[10,12,16], a disease duration > 15 years[12,15,16], 
surgical interventions[11–13], and immunomodulator use[16] 
have been reported to be associated with work disability 
in patients with IBD. 
In UC, an age > 55 years was associated with 
work disability, which might not be directly disease 
related. Indeed, it has been reported that disability 
Table 4  Univariate and multivariate regression analyses of full and partial work disability in patients with Crohn’s disease n  (%)
Full disability Partial disability Unadj. OR (95%CI) Adj. OR (95%CI)
n 342 (100) 129 (100)
Sex (female) 251 (73) 100 (78) 0.80 (0.50-1.29) - 
Age 
   < 40 yr 110 (32) 54 (42) 1.00 1.00
   40-55 yr 137 (40) 61 (47) 1.10 (0.71-1.72) 1.05 (0.65-1.70)
   > 55 yr 95 (28) 14 (11) 3.33 (1.74-6.37) 3.06 (1.54-6.07)
Age at diagnosis
   A1: diagnosis ≤ 16 yr 28 (8) 13 (10) 1.00 -
   A2: diagnosis 17-40 yr 256 (75) 103 (80) 1.15 (0.58-2.32)  
   A3: diagnosis > 40 yr 58 (17) 13 (10) 2.07 (0.85-5.05)   
Disease duration 
   ≤ 15 yr 151 (44) 65 (50) 1.00 -
   > 15 yr 191 (56) 64 (50) 1.28 (0.86-1.93) 
Education 332 (100) 128 (100)
   Low 236 (71) 73 (57)  1.85 (1.21-2.83)  1.62 (1.02-2.58)
Smoking 323 (100) 115 (100)
   Yes 125 (39) 33 (29) 1.57 (0.99-2.49)  1.53 (0.93-2.50)
Disease location
   L1: ileal disease1 56 (19) 21 (19) 1.00 -
   L2: colon disease1 80 (28) 38 (35) 0.79 (0.42-1.49)  
   L3: ileocolon disease1 155 (53) 50 (46) 1.16 (0.64-2.11) 
   L4: upper GI disease2 38 (11) 8 (6) 1.89 (0.86-4.17) -
   P: peri-anal disease2 109 (32) 45 (35) 0.87 (0.57-1.34) -
Disease behavior CD
   Fistulising disease2 64 (19) 23 (18) 1.06 (0.63-1.80) -
   Stricturing disease2 92 (27) 33 (26) 1.07 (0.67-1.70) -
   Penetrating disease2 47 (14) 19 (15) 0.92 (0.52-1.64) -
   Pouch2 6 (1.8) 4 (3) 0.56 (0.15-2.01) -
   Stoma2 69 (20) 20 (16) 1.38 (0.80-2.38) -
   Surgery2 192 (56) 64 (50) 1.30 (0.87-1.95) -
Medication 335 (100) 125 (100)
   Anti-TNFα 193 (58) 68 (54) 1.14 (0.75-1.72) -
   Immunomodulators 249 (74) 87 (70) 1.26 (0.80-1.99) -
   Extra-intestinal manifestations2 152 (44) 50 (39) 1.26 (0.84-1.91) -
   PSC2 2 (0.6) 4 (3) 0.18 (0.03-1.02) 0.19 (0.03-1.10)
   Complications2 106 (31) 34 (26) 1.25 (0.80-1.98) -
1These percentages are calculated for 291 patients with CD that were fully disabled and 109 patients with CD that were partially disabled; 2Missing values 
were scored as non-present. CD: Crohn’s disease; Unadj: Unadjusted; TNFα: Tumor necrosis factor alpha; PSC: Primary sclerosing cholangitis.
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pensions were not caused by UC but often by other 
age-related comorbidities[11,12]. On the other hand, in 
CD it has been found that patients with CD receive 
their disability pension because of IBD or other IBD 
related comorbidity[11], rather than other age related 
comorbidities.
Surgical interventions were a risk factor for work 
disability in patients with CD, but not in UC. As surgery 
is an indicator of severe disease these data seemed 
to corroborate the hypothesis that severity of disease 
predicts work disability. In line with this, higher work 
disability rates have been reported after colectomy in 
patients with UC[14]. A recent review has shown that 
surgical rates have declined since the introduction of 
biologicals, indicating a beneficial effect of treatment 
with biologicals on disease outcome[20]. Our study is 
not well suited to study this effect, since our most 
reliable clinical information has been collected after 
the introduction of biologicals. Other studies report 
no differences in disability between patients receiving 
anti-TNFα treatment or patient that underwent 
surgery[21,22]. At the moment, a clinical trail (LIRIC) 
assesses differences in outcome comparing anti-TNFα 
treatment with Ileocecal resection in patients with CD 
not responsive to prednisolone[23]. 
While it has been established that anti-TNFα 
and/or immunomodulators are generally used to ma-
intain remission in patients with IBD, our study found 
an association between use of anti-TNFα use and 
(full) work disability. This could be due to selection 
bias, as all patients were treated in tertiary referral 
centers, with most of them having extensive disease 
involvement (Montreal classification; 47% L3 and 58% 
E3). Therefore, it is likely that patients receiving anti-
TNFα and immunomodulator therapy are patients with 
more severe disease, receiving “rescue therapy” rather 
than “top-down therapy”. Smoking was found to be 
a risk factor for work disability in CD, but not in UC. 
In this study, smoking status was scored at moment 
of inclusion, as it has been known that smoking can 
increase frequency and severity of flares in CD[24], 
while it can ameliorate disease in UC[25]. It has been 
reported that smoking at diagnosis was associated 
with work disability in UC[13], whereas others reported 
on an association between numbers of sick leave days 
and smoking at the onset of CD[16], corroborating the 
current findings.
Clinical risk factor for long-term full work disability
We replicated most known, clinical risk factors for 
work disability and evaluated risk factors for long-
term full work disability (> 80% work disability) 
comparing it to partial work disability (> 35% work 
disability). A lower education level was the only factor, 
Table 5  Univariate and multivariate regression analyses of work disability in patients with ulcerative colitis n  (%)
Work disability Employed Unadj. OR (95%CI) Adj. OR (95%CI)
n   214 (100)   664 (100)
Sex (female)  124 (58) 333 (50)    1.37 (1.00-1.87)    1.76 (1.23-2.53)
Age 
   < 40 yr   58 (27) 287 (43) 1.00 1.00
   40-55 yr   94 (44) 277 (42)    1.68 (1.16-2.42)    1.52 (0.97-2.40)
   > 55 yr   62 (29) 100 (15)    3.07 (2.01-4.69)    2.93 (1.68-5.14) 
Age at diagnosis
   A1: diagnosis ≤ 16 yr 18 (8)  64 (10) 1.00 1.00
   A2: diagnosis 17-40 yr 124 (58) 474 (71)    0.93 (0.53-1.63)   1.06 (0.55-2.04)
   A3: diagnosis > 40 yr  72 (34) 126 (19)    2.03 (1.12-3.69)   1.99 (0.92-4.28)
Disease duration 
   ≤ 15 yr 129 (60) 439 (66) 1.00 -
   > 15 yr   85 (40) 225 (34)    1.29 (0.94-1.77)
Education   208 (100)   656 (100)
   Low 144 (69) 282 (43)    2.98 (2.14-4.16)    2.59 (1.81-3.70)
Smoking   206 (100)   621 (100)
   Yes  30 (15)   71 (11)    1.32 (0.83-2.09) -
Disease location
   E1: proctitis1 14 (7) 54 (9) 1.00 -
   E2: left-sided colitis1   54 (27) 215 (37)       97 (0.50-1.87)
   E3: extensive colitis1 130 (66) 317 (54)    1.58 (0.85-2.95)
   Pouch2   37 (17) 54 (8)    2.36 (1.50-3.71)   1.72 (0.81-3.65)
   Stoma2   35 (16) 54 (8)    2.21 (1.40-3.49)    1.13 (0.54-2.38)
   Surgery2   60 (28)  97 (15)    2.28 (1.58-3.29)    1.68 (0.75-3.75)
Medication    211 (100)  649 (100)
   Anti-TNFα   53 (25) 120 (18)    1.48 (1.02-2.14)  1.33 (0.86-2.06)
   Immunomodulators 139 (66) 350 (54)    1.65 (1.19-2.28)  1.58 (1.09-2.28)
   Extra-intestinal manifestations2   78 (36) 130 (20)    2.36 (1.68-3.30)   2.13 (1.47-3.09)
   PSC2   8 (4) 21 (3)    1.19 (0.52-2.73) -
   Complications2   37 (17)  89 (13)     1.35 (0.89-2.05) -
1These percentages are calculated for 198 patients with UC that were disabled for work and 586 patients with UC that were employed; 2Missing values were 
scored as non-present. UC: Ulcerative colitis; Unadj: Unadjusted; Adj: Adjusted; TNFα: Tumor necrosis factor alpha; PSC: Primary sclerosing cholangitis.
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which remained statistically significantly associated 
with long-term full work disability in CD. In only a few 
studies, educational level has been taken into account 
showing conflicting results. A higher education level 
seemed to be associated to work disability and sick 
leave in patients with CD in previous studies[8,13]. On 
the other hand, a study by Vester-Andersen et al. 
reported no patients with CD with a higher education 
level that were receiving a disability pension[13]. Hence, 
the relationship between education level and work 
disability remains unclear, and more population specific 
studies are needed before hard conclusions can be 
drawn[26,27]. 
Risk factors identified in this report should be 
interpreted with caution, as the confidence intervals 
were quite large and data were derived from third-line 
referral centres. Furthermore, due to the nature of our 
data we could not distinguish between work disability 
solely attributable to IBD, or work disability due to 
a different cause. However, the median age in our 
study was 40 years for CD patients and 43 years for 
UC patients, ages at which age-related comorbidities 
are generally low. Furthermore, we did not score how 
physically heavy the patients’ jobs were, known to 
contribute to work disability. Moreover, the reason 
for work disability was unknown.  It could have been 
that sick leave (< 2 years), was caused by another 
reason than IBD, for example pregnancy leave or 
psychological health problems. When comparing 
our data from the Dutch social security system with 
the more widely used Work Productivity and Activity 
Impairment Questionnaire (WPAI), the main difference 
lies within the objectivity of the data from the Dutch 
social security system, since it is assessed by a 
physician as opposed to the more subjective WPAI, 
which is patient reported. A main disadvantage of the 
data from the Dutch social security system is that it 
makes no distinction between work disability due to 
IBD or due to a different cause. Furthermore, the WPAI 
assesses activity, not solely work related, on a weekly 
basis, providing more insight in the disease course. 
The strength of our study is the extended disease 
and patient documentation by the clinician. 
In conclusion, in this study we show a higher pre-
valence of work disability in IBD compared to the 
general Dutch population. Furthermore, we identified 
risk factors associated with work disability, with a lower 
level of education being a risk factor for long-term 
full work disability in CD, and disease complications 
being a risk factor for long-term full work disability in 
UC. In future studies web-based follow-up of Patient-
Reported Outcome Measurements (PROMs) including 
Table 6  Univariate and multivariate regression analyses of full and partial work disability in patients with ulcerative colitis n  (%)
Full disability Partial disability Unadj. OR (95%CI) Adj. OR (95%CI)
n 124 (100) 54 (100)
Sex (female) 75 (60) 26 (48) 1.65 (0.87-3.14) -
Age 
   < 40 yr 25 (20) 15 (28) 1.00 1.00
   40-55 yr 52 (42) 32 (59) 0.98 (0.45-2.12) 0.90 (0.40-2.03)
   > 55 yr 47 (38) 7 (13) 4.03 (1.45-11.17) 3.49 (1.23-9.92)
Age at diagnosis
   A1: diagnosis ≤ 16 yr 7 (6) 5 (9) 1.00 -
   A2: diagnosis 17-40 yr 70 (56) 34 (63) 1.47 (0.43-4.97)
   A3: diagnosis > 40 yr 47 (38) 15 (28) 2.24 (0.62-8.10)
Disease duration 
   ≤ 15 yr 65 (52) 36 (67) 1.00 1.00
   > 15 yr 59 (48) 18 (33) 1.82 (0.93-3.54) 1.78 (0.87-3.62)
Education 122 (100) 50 (100)
   Low 84 (69) 37 (74) 0.78 (0.37-1.63) -
Smoking 121 (100) 52 (100)
   Yes 18 (15) 7 (13) 1.12 (0.44-2.88) -
Disease location
   E1: proctitis1 9 (8) 4 (8) 1.00 -
   E2: left-sided colitis1 39 (33) 9 (18) 1.93 (0.48-7.68) -
   E3: extensive colitis1 70 (59) 38 (74) 0.82 (0.24-2.84) -
   Pouch2 24 (19) 9 (17) 1.20 (0.52-2.79)  -
   Stoma2 23 (19) 8 (15) 1.31 (0.54-3.15) -
   Surgery2 37 (30) 14 (26) 1.22 (0.59-2.50)  -
Medication 122 (100) 53 (100)
   Anti-TNFα 30 (25) 10 (19) 1.40 (0.63-3.13)  -
   Immunomodulators 77 (63) 37 (70) 0.74 (0.37-1.48)  -
   Extra-intestinal manifestations2 51 (41) 19 (35) 1.29 (0.66-2.50)  -
   PSC2 3 (2) 4 (7) 0.31 (0.07-1.44) -
   Complications2 28 (23) 4 (7) 3.65 (1.21-10.97) 3.39 (1.09-10.58)
1These percentages are calculated for 118 patients with UC that were fully disabled and 51 patients with UC that were partially disabled; 2Missing values 
were scored as non-present. UC: Ulcerative colitis; Unadj: Unadjusted; Adj: Adjusted; TNFα: Tumor necrosis factor alpha; PSC: Primary sclerosing 
cholangitis.
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clinical disease activity scores, could be promising tool 
for detecting a decline in work activity due to disease 
activity.  
COMMENTS
Background
Inflammatory bowel disease (IBD), consisting of Crohn’s disease (CD) and 
ulcerative colitis (UC) is a heterogeneous/multifaceted disease. Patients suffer 
from symptoms like diarrhoea, abdominal pain, fatigue, and weight loss. IBD 
generally makes its debut during the second or third decade of life. Therefore, 
patients with IBD can encounter major problems during their economically 
productive life, which can lead to work disability, sometimes at young age. 
Preventing work disability is therefore an important goal in IBD management. 
Research frontiers
Work disability rates have been reported before, but reported rates are 
heterogeneous, ranging between 5% and 33% depending on sample size, 
methodology, and study population. However, in most study designs, risk factors 
for any form of work disability are the focus of interest, neglecting risk factors 
associated specifically with long-term full work disability (> 80% work disability 
for > 2 years).  This study assesses the prevalence of work disability in patients 
with IBD and to compare this with the general Dutch population, and secondly 
this study tries to identify risk factors for work disability, especially risk factors 
for long-term full work disability.
Innovations and breakthroughs
In patients with IBD, the overall proportion of work disability was 29% in CD, 
and 19% in UC. These work disability rates were higher than those in the age-
adjusted general Dutch population (7%). Suffering from (severe) IBD may in 
itself be explanatory for this higher percentage. Furthermore, all patients in 
the Dutch IBD Biobank were treated in tertiary referral centers with a severe 
disease course signature: 47% ileocolonic disease (L3 Montreal CD) and 58% 
extensive colitis (E3 Montreal UC). The authors replicated most known, clinical 
risk factors (female sex, an age > 40 years at diagnosis, older age at inclusion, 
a lower education level, extra-intestinal manifestations, a disease duration > 
15 years surgical interventions, and immunomodulator use) for work disability. 
A lower education level was the only factor, which remained statistically 
significantly associated with long-term full work disability in CD. In patients with 
UC disease complications were associated with long-term full work disability.  
Applications
This study shows that a lower education is patients with CD, and disease 
complications (osteopenia, thromboembolic event) in patients with UC are 
associated with long-term full work disability (> 80% work disability for > 2 
years). This highlights the need for early assessment of risk factors for work 
disability, as work disability is substantial among IBD patients and associated 
with high societal health care costs and lower quality of life. In future studies 
web-based follow-up of Patient-Reported Outcome Measurements (PROMs) 
including clinical disease activity scores, could be a promising tool for detecting 
a decline in work activity due to disease activity.   
Terminology 
To identify risk factors for work disability we categorized the variable 
employment status into two groups; employed (both full time and part time) 
versus disabled for work (including partial disability, full disability and sick 
leave). To evaluate risk factors for long-term full work disability, we compared 
risk factors for long-term full work disability (> 80% work disability) to risk 
factors for partial work disability (> 35% work disability).   
Peer-review
In this paper, the authors investigate the prevalence of and risk factors for 
partial and full work disability in Dutch patients with IBD. The manuscript is 
complete and well written, and it is expected to improve our knowledge of 
the health economics of IBD. This is a well-written paper exploring a rapidly 
evolving area of IBD research. The inherent limitations of this study are 
somewhat understandable and provide further direction to research in this 
important area.
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